Home » Topics » BioWorld Science

BioWorld Science
RSS

Disappointing preliminary phase IIa results for NGD-2000-1 in RA

June 18, 2004

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

June 18, 2004

Vasogen updates Celacade phase III program

June 18, 2004

Enzon strengthens pipeline during Q3 through Onco TCS addition

June 18, 2004

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

June 18, 2004

Treatment options for restless legs syndrome

June 18, 2004

Dopamine D4 receptor agonist ABT-724 may offer safe and effective treatment of erectile dysfunction

June 18, 2004

GPC Biotech achieves significant progress in anticancer drug programs during first quarter

June 18, 2004

Novel fructose 1,6-bisphosphatase inhibitor lowers blood glucose in vivo

June 18, 2004

Polyvalent vaccine reported to improve survival in advanced melanoma

June 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...